Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 214

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1A
Chunk 214
---
 able to sell their common stock at or above the price at which they paid. The market price for our common stock may be influenced by those factors discussed in this “Risk Factors” section and many others, including: 

•our ability to enroll subjects in our ongoing and planned clinical trials; 

•results of our clinical trials and preclinical studies, and the results of trials of our competitors or those of other companies in our market sector; 

•failure to meet or exceed drug development or financial projections we provide to the public or of the investment community;

•regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process; 

•regulatory or legal developments in the United States and foreign countries; 

•changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system; 

•the success or failure of our efforts to acquire, license or develop additional product candidates; 

•innovations or new products developed by us or our competitors; 

•announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; 

•manufacturing, supply or distribution delays or shortages; 

•any changes to our relationship with any manufacturers, suppliers, future collaborators or other strategic partners; 

•achievement of expected product sales and profitability; 

•variations in our financial results or those of companies that are perceived to be similar to us; 

•market conditions in the pharmaceutical sector and issuance of securities analysts’ reports or recommendations; 

•trading volume of our common stock; 

•an inability to obtain additional funding; 

•sales of our stock by us, insiders and stockholders; 

•changes in accounting principles;

•general economic, industry and market conditions or other events or factors, many of which are beyond our control, such as the impact of any natural disasters, including related to climate change, or public health emergencies, inflation, interest rates, actual or anticipated bank failures, and international military conflicts, including between Russia and Ukraine and in the Middle East; 

•additions or departures of key personnel; and 

•intellectual property, product liability or other litigation by or against us. 

In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management’s attention and resources,